# **SERIAL NO.** 10/775,481 **FILED:** February 10, 2004

### REMARKS

#### Status of the Claims

Claims 1-131 are pending.

Claims 1-131 have been subject to a restriction requirement

By way of this amendment, claims 1-63, 66, 67 and 104-131 have been canceled, claims 68-74, 76, and 79-103 have been amended, and new claims 132-144 have been added.

Upon entry of this amendment, claims 64, 65, 68-103 and 132-144 will be pending.

# **Summary of the Amendment**

Claims 68, 71-74, 76, and 79-103 have been amended to delete references to canceled claims.

Claims 69 and 70 have been amended to change dependence from a canceled claimed to a pending claim.

Claim 74 has been amended to include reference to antibody fragments. Support is found throughout the specification as filed such as in paragraph 105 of the published application.

New claims 132-144 have been added to refer to specific embodiments of the invention. Support is found throughout the specification and claims as filed No new matter has been added..

## **Restriction Requirement**

Restriction has been required to a single group of the seven groups set forth in the Official Action. Applicant hereby elects Group 6 for examination. The subject matter of Groups 1-5 and 7 have been canceled and reserved for inclusion in a divisional application.

### **Election of Species**

Elections have been required for several different aspects of the invention.

DOCKET NO. TJU0016-100/WAL SCO.008

**PATENT** 

**SERIAL NO.** 10/775,481

FILED: February 10, 2004

Election has been required for the mode of administration. Applicant hereby elects

intravenous as the elected route. Claims 64, 65, 68-70, 72, 74-103 and 132-144 each read on the

elected species.

Election has been required for the specific ST receptor ligand. Applicant hereby elects

anti-ST antibodies and fragments thereof. Claims 64, 65, 68-75, 79-103, 132-135 and 138-144

each read on the elected species.

Election has been required for the cancer to be treated. Applicant hereby elects

metastatic colorectal cancer. Claims 64, 65, 68-103 and 132-144 each read on the elected

species.

Election has been required for the therapeutic agent. Applicant hereby elects 5-

fluorouracil. Claims 68, 69, 132-137 and 140-143 each read on the elected species.

Conclusion

Claims 64, 65, 68-103 and 132-144 are in condition for allowance. A notice of allowance

is earnestly solicited.

The Commissioner is hereby authorized to charge any deficiencies of fees and credit of

any overpayments to Deposit Account No. 50-0436.

Respectfully submitted,

/Mark DeLuca, Reg. No. 33,229/

Mark DeLuca

Registration No. 33,229

Dated: August 3, 2007 PEPPER HAMILTON, LLP

500 Grant Street, 50<sup>th</sup> Floor

Pittsburgh, PA 15219

Telephone: 610-640-7855

11